Business
PRTC's New Candidate: Oral CBD for Epilepsy/CNS
PRTC's New Candidate: Oral CBD for Epilepsy/CNS.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n 30 November 2022\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech's Glyph™ Platform\n \n \n \n \n \n LYT-310 demonstrated three to fourfold increase in oral bioavailability of CBD compared to unmodified CBD in a preclinical model\n \n \n \n \n \n Oral dosing and potential for improved tolerability could expand therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders\n \n \n \n \n \n Further proof of Glyph platform's ability to enable oral administration of certain small molecules with otherwise limited oral bioavailability\n \n \n \n \n \n \n PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTech's Glyph™ platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Q4 of 2023.\n \n \n \n \n \n A CBD-based product has received regulatory approval in the United States and Europe to treat seizures resulting from certain rare conditions, but it requires a large volume of a sesame oil-based formulation, which limits its use in broader indications and age groups. PureTech's LYT-310 is designed to greatly expand the therapeutic application and potential of CBD by:\n \n \n enabling oral administration in a capsule;\n expanding the use of CBD into a broad range of therapeutic areas and patient populations (such as adolescents and adults) where higher doses are required to achieve a therapeutic effect;\n potentially improving safety and reducing gastrointestinal (GI) tract side effects that are associated with the currently approved CBD-based treatment by reducing GI and liver exposure; and\n allowing for a readily scalable, consistent product in a cost-effective manner.\n \n \n \n \n \n \"The nomination of LYT-310 is an exciting expansion of PureTech's Glyph technology,\" said Daniel Bonner, Ph.D., Vice President at PureT...